Qiagen NV (QGEN) Enters Deal with Eli Lilly (LLY)

Article Related Press Releases (1) Stock Quotes (2) Comments (0)

Qiagen NV (NASDAQ: QGEN) entered into a master collaboration agreement with Eli Lilly and Company (NYSE: LLY) for the development and commercialization of companion diagnostics for pairing with Lilly investigational and approved medicines across all therapeutic areas. The agreement builds on QIAGEN and Lilly's past work together. Companion diagnostics unlock a patient's molecular information in order to guide treatment decisions for specific cancers or other diseases. Financial terms of the agreement are not being disclosed.

The agreement provides a framework for Lilly and QIAGEN to collaborate on future projects - across all of Lilly's therapeutic areas - aimed at bringing to market Lilly medicines paired with QIAGEN diagnostics. It also further underscores QIAGEN's leading position in partnering with global pharmaceutical companies to deliver the benefits of personalized medicine to patients and healthcare providers.

---

Join StreetInsider.com FREE and get immediately alerted when news breaks on your stocks and other market items - JOIN NOW

---

*NEW - Download StreetInsider's FREE iPhone and iPad App - Click Here

---

---

You May Also Be Interested In

• Salix Pharma (SLXP) Reports Positive Results From Two Budesonide Foam Phase 3s
• Cleantech Solutions (CLNT) Becomes Certified Supplier to Sinopec and CPNC
• Canadian Solar (CSIQ) Continues Higher Following Arbitration Win Over LDK (LDK)

Create E-mail Alert Related Categories

Corporate News, FDA

Add Your Comment

Name

Subject

Body

Share on Facebook

Verification
can't see the text?
click here to refresh the image.
what's this?